Joint effect of peroxisome proliferator-activated receptor c genetic polymorphisms and estrogen-related risk factors on breast cancer risk:results from a case-control study in Taiwan

MUIR > Graduate Institute of Health Care > Department of Health Business Administration > Papers > Item 987654321/1273

Please use this identifier to cite or link to this item: http://ir.meiho.edu.tw/ir/handle/987654321/1273

Title:	Joint effect of peroxisome proliferator-activated receptor c genetic polymorphisms and estrogen-related risk factors on breast cancer risk:results from a case-control study in Taiwan
Authors:	Mei-Hsuan Wu;Chi-Hong Chu;Yu-Ching Chou;Wan-Yun Chou;Tsan Yang;Giu-Cheng Hsu;Cheng-Ping Yu;Jyh-Cherng Yu;Chien-An Sun
Keywords:	Breast cancer;Case–control study;Haplotype;Polymorphism;Peroxisome proliferatoractivated receptor c
Date:	2011
Issue Date:	2011-09-30T08:05:02Z (UTC)
Abstract:	eroxisome proliferator-activated receptor c (PPARc) has been linked with possible antineoplastic effects in colorectal carcinogenesis. However, data for the possible link between PPARc and breast cancer risk are sparse. We assessed the association of three polymorphisms in PPARc (rs10865710 [C-681T], rs1805192 [Pro12Ala], and rs3856806 [C1431T]) with the risk of breast cancer in an ethnic Chinese female population in Taiwan. In addition, interactions with estrogen exposures were also explored. Genotypes for the PPARc polymorphisms were determined on 291 incident breast cancer cases and 589 matched controls by fluorogenic 50-nuclease assay. The at-risk haplotypes were defined according to the three polymorphisms in the following order: C-681T, Pro12Ala, and C1431T, which include CCT, GGT, and GGC. In addition, a critical period of estrogen exposure was estimated by the interval between age at menarche and age at first full-term pregnancy. Overall, there was no evidence of a significant impact of individual polymorphisms of PPARc on breast cancer risk. However, the haplotype analysis revealed that women harboring at-risk haplotypes showed a significant 67% increase in breast cancer risk [adjusted odds ratio (OR) 1.67; 95% confidence interval (CI) 1.11–2.52]. Furthermore, there was a significant joint effect of estrogen exposure-related factors and atrisk haplotypes of PPARc on breast cancer risk (adjusted OR 4.04; 95% CI 1.89–8.65), particularly in premenopausal women. The present study implicates a role for PPARc in breast cancer risk. Mechanistic studies to fully elucidate the mechanisms underlying PPARc’s effects should be pursued in future investigations.
Relation:	Breast Cancer Res Treat (2011) 127:777–784
Appears in Collections:	[Department of Health Business Administration] Papers

Files in This Item:

There are no files associated with this item.

Loading...